1. Current Status, Position

• Medical Director and Head of the Dept. of Hematology, Oncology, and Tumor Immunology, Robert Rössle Clinic, HELIOS Klinikum Berlin-Buch
• Chairman of the DCGMA.

2. Education

1979: University Degree of a Medical Doctor and License to Practise,Free University of Berlin, FRG
1979-1981: Dept. of Experimental Pharmacology at the Free University of Berlin, FRG
1982: Ph.D. degree in Medicine, Free University of Berlin, FRG
1981-1988: Clinical resident in the Dept. of Hematology and Oncology, University Clinic Steglitz, Free
University of Berlin, FRG
1988: Degree for specialisation in Internal Medicine
1989: Degree for specialisation in Transfusion Medicine
1990: Habilitation for Internal Medicine, Free University of Berlin, FRG
1992: Degree for specialisation in Hematology and Oncology
December 1993-March 2001: Deputy Medical Director, Dept. of Medical Oncology and Applied
Molecular Biology (renamed 1996: Dept. of Hematology, Oncology, and Tumor Immunology), Robert
Rössle Clinic, Charité, Campus Berlin-Buch, FRG
Since 1994: Full Professor of Hematology/Oncology and Applied Molecular Biology with unlimited
tenure, Humboldt University of Berlin
Since April 2001: Medical Director and Head of the Dept. of Hematology, Oncology, and Tumor
Immunology, Robert Rössle Clinic, HELIOS Klinikum Berlin-Buch, Charité, Campus Berlin-Buch, FRG
1994: Founding member of the "European Group for the Immunological Characterization of
Leukemias" (EGIL)
Since December 1999: in the board of the Drug Commission of the German Medical Association (DCGMA)
2002-2005: Full member and chairman of the Panel of Experts at the German Ministry of Health dealing with off label use of drugs
Since 2004: Member of the Scientific Advisory Group-Oncology at the European Medicines Agency (EMA); member of the Scientific Advisory Group (SAG)-Oncology
Since 2006: Chairman of the Drug Commission of the German Medical Association (DCGMA)
Since 2013: Member of the Management Board of the European Medicines Agency (EMA)

3. Research Area

Prof. Dr. Ludwig focuses his work on the following research areas:

• Biologic determinants of treatment response in acute leukemias (e.g., expression and function of apoptosis-related regulatory molecules, minimal residual disease); functional genomics both in translational research and model systems of acute leukemia (coordinator of the Acute Leukemia Consortium within the NGFN, National Genome Research Net).
• Innovative treatment strategies in oncology (e.g., bispecific monoclonal antibodies, targeted therapy).
• Pharmacovigilance, especially postmarketing surveillance; international harmonization of drug regulation/approvals.
• Issues of medical ethics and professional norms regarding academic-industry collaboration.